Hosted on MSN2d
Health Canada approves GSK’s Ojjaara for myelofibrosis in anaemia patients
Health Canada has granted approval for GlaxoSmithKline’s (GSK) Ojjaara (momelotinib) for treating myelofibrosis (MF) in ...
Too Old to Operate7d
Navigating Challenges in HSCT Eligibility for Myelofibrosis
Updated guidelines on allogeneic hematopoietic stem cell transplantation for myelofibrosis examine spleen-related ...
news.stv18h
Donor appeal: 'Thought that I might not be here for my daughter is terrifying'
Rachael Nixon desperately needs to find a stem cell donor, after being diagnosed with a rare and aggressive form of blood ...
Business Wire2d
Opna Bio Announces 2024 ASH Presentations Highlighting Interim Data from Phase 1 Combo Study of BET Inhibitor OPN-2853 with Ruxolitinib in Myelofibrosis, and Promising ...
Investigator-sponsored study Title: “PROMise Trial: Interim analysis of PROMise, a clinical study combining the BET inhibitor OPN-2853 with ruxolitinib in patients with advanced myelofibrosis ...
Medpage Today on MSN12d
Asymptomatic or Minimally Symptomatic Myelofibrosis
About 20% of patients with myelofibrosis initially have no symptoms, allowing many cases to exist under the clinical suspicion of primary care clinicians. The need to treat asymptomatic or minimally ...
Daily1d
GSK Ojjaara approved in Canada for treatment of myelofibrosis in adults who have moderate to severe anemia
Mississauga: GSK has announced that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...
Too Old to Operate17d
Fedratinib as a Second-Line Treatment for Myelofibrosis After Ruxolitinib Intolerance
The following is a summary of “Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open label, randomized, ...
Pharmabiz2d
Health Canada approves GSK’s Ojjaara for the treatment of myelofibrosis in adults who have moderate to severe anaemia
Mississauga, Ontario Thursday, November 14, 2024, 09:00 Hrs [IST] ...
Targeted Oncology11d
Phase 1 Study of Type II JAK2 Inhibitor in Myelofibrosis Enrolls First Patient
The study is evaluating AJ1-11095, a novel agent for the treatment of myelofibrosis that did not respond to or relapsed ...
Ojjaara (momelotinib) approved in Canada for the treatment of myelofibrosis in adults who have moderate to severe anemia
CNW/ - GSK announced today that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...